BACKGROUND: Leukocyte activation results in a rapid increase in adhesion to the extracellular matrix due to the activation of beta 1 integrin receptors. A role for phosphatidylinositol (PI) 3-kinase in integrin activation has been proposed, as activation of integrins by many receptors can be blocked by PI 3-kinase inhibitors. One receptor that regulates integrins is the CD28 surface antigen; here, we investigated the mechanisms responsible for CD28-mediated integrin activation. RESULTS: CD28-mediated integrin activation was blocked by mutation of the binding site for the p85 catalytic subunit of PI 3-kinase in the CD28 cytoplasmic domain, and by expression of a dominant-negative form of the p85 subunit. Substitution of the Src homology 2 (SH2)-binding motif in the CD28 cytoplasmic domain for the corresponding motif in the CD28-related CTLA-4 surface antigen also blocked integrin activation but did not affect the recruitment and activation of PI 3-kinase. Mutations of the CD28 cytoplasmic domain that blocked integrin activation also impaired the tyrosine phosphorylation of the Cbl adaptor protein and the activation of the PI 3-kinase that was associated with Cbl. This Cbl-associated PI 3-kinase was distinct from the PI 3-kinase that coprecipitated with the CD28 cytoplasmic domain. CD28-mediated activation of beta 1 integrins was inhibited by expression of a mutant Cbl protein that shows reduced association with PI 3-kinase. CONCLUSIONS: Cbl is required for PI-3-kinase-dependent regulation of integrin receptors by CD28. Furthermore, CD28 is coupled to two distinct pools of PI 3-kinase, one directly associated with the CD28 cytoplasmic tail and the other associated with Cbl.
BACKGROUND: Leukocyte activation results in a rapid increase in adhesion to the extracellular matrix due to the activation of beta 1 integrin receptors. A role for phosphatidylinositol (PI) 3-kinase in integrin activation has been proposed, as activation of integrins by many receptors can be blocked by PI 3-kinase inhibitors. One receptor that regulates integrins is the CD28 surface antigen; here, we investigated the mechanisms responsible for CD28-mediated integrin activation. RESULTS:CD28-mediated integrin activation was blocked by mutation of the binding site for the p85 catalytic subunit of PI 3-kinase in the CD28 cytoplasmic domain, and by expression of a dominant-negative form of the p85 subunit. Substitution of the Src homology 2 (SH2)-binding motif in the CD28 cytoplasmic domain for the corresponding motif in the CD28-related CTLA-4 surface antigen also blocked integrin activation but did not affect the recruitment and activation of PI 3-kinase. Mutations of the CD28 cytoplasmic domain that blocked integrin activation also impaired the tyrosine phosphorylation of the Cbl adaptor protein and the activation of the PI 3-kinase that was associated with Cbl. This Cbl-associated PI 3-kinase was distinct from the PI 3-kinase that coprecipitated with the CD28 cytoplasmic domain. CD28-mediated activation of beta 1 integrins was inhibited by expression of a mutant Cbl protein that shows reduced association with PI 3-kinase. CONCLUSIONS:Cbl is required for PI-3-kinase-dependent regulation of integrin receptors by CD28. Furthermore, CD28 is coupled to two distinct pools of PI 3-kinase, one directly associated with the CD28 cytoplasmic tail and the other associated with Cbl.
Authors: Robert E Dejournett; Ryuji Kobayashi; Shujuan Pan; Chuanfen Wu; Laurence D Etkin; Richard B Clark; Oliver Bögler; Jian Kuang Journal: Biochem J Date: 2007-01-15 Impact factor: 3.857
Authors: Eun Young Choi; Valeria V Orlova; Susanna C Fagerholm; Susanna M Nurmi; Li Zhang; Christie M Ballantyne; Carl G Gahmberg; Triantafyllos Chavakis Journal: Blood Date: 2008-01-31 Impact factor: 22.113
Authors: Kirsty Ford; Christopher J Hanley; Massimiliano Mellone; Cedric Szyndralewiez; Freddy Heitz; Philippe Wiesel; Oliver Wood; Maria Machado; Maria-Antoinette Lopez; Anusha-Preethi Ganesan; Chuan Wang; Ankur Chakravarthy; Tim R Fenton; Emma V King; Pandurangan Vijayanand; Christian H Ottensmeier; Aymen Al-Shamkhani; Natalia Savelyeva; Gareth J Thomas Journal: Cancer Res Date: 2020-03-02 Impact factor: 12.701
Authors: Emily K Griffiths; Otto Sanchez; Pleasantine Mill; Connie Krawczyk; Carlo V Hojilla; Evelyn Rubin; Marion M Nau; Rama Khokha; Stan Lipkowitz; Chi-Chung Hui; Josef M Penninger Journal: Mol Cell Biol Date: 2003-11 Impact factor: 4.272